Orgenesis (ORGS) Competitors $2.01 0.00 (0.00%) As of 05/20/2025 03:39 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsSustainabilityTrendsBuy This Stock ORGS vs. ESLA, ALZN, OSTX, RVPH, CELU, ITRM, TNYA, NRXP, ELYM, and RANIShould you be buying Orgenesis stock or one of its competitors? The main competitors of Orgenesis include Estrella Immunopharma (ESLA), Alzamend Neuro (ALZN), OS Therapies (OSTX), Reviva Pharmaceuticals (RVPH), Celularity (CELU), Iterum Therapeutics (ITRM), Tenaya Therapeutics (TNYA), NRx Pharmaceuticals (NRXP), Eliem Therapeutics (ELYM), and Rani Therapeutics (RANI). These companies are all part of the "pharmaceutical products" industry. Orgenesis vs. Estrella Immunopharma Alzamend Neuro OS Therapies Reviva Pharmaceuticals Celularity Iterum Therapeutics Tenaya Therapeutics NRx Pharmaceuticals Eliem Therapeutics Rani Therapeutics Estrella Immunopharma (NASDAQ:ESLA) and Orgenesis (NASDAQ:ORGS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, community ranking, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations. Does the MarketBeat Community favor ESLA or ORGS? Estrella Immunopharma and Orgenesis both received 1 outperform votes by MarketBeat users. CompanyUnderperformOutperformEstrella ImmunopharmaOutperform Votes1100.00% Underperform VotesNo VotesOrgenesisOutperform Votes1100.00% Underperform VotesNo Votes Does the media prefer ESLA or ORGS? In the previous week, Orgenesis had 1 more articles in the media than Estrella Immunopharma. MarketBeat recorded 1 mentions for Orgenesis and 0 mentions for Estrella Immunopharma. Estrella Immunopharma's average media sentiment score of 0.00 beat Orgenesis' score of -0.71 indicating that Estrella Immunopharma is being referred to more favorably in the media. Company Overall Sentiment Estrella Immunopharma Neutral Orgenesis Negative Which has more volatility & risk, ESLA or ORGS? Estrella Immunopharma has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500. Comparatively, Orgenesis has a beta of 0.72, meaning that its stock price is 28% less volatile than the S&P 500. Do analysts rate ESLA or ORGS? Estrella Immunopharma currently has a consensus target price of $16.00, indicating a potential upside of 1,484.16%. Given Estrella Immunopharma's stronger consensus rating and higher probable upside, analysts plainly believe Estrella Immunopharma is more favorable than Orgenesis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Estrella Immunopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Orgenesis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is ESLA or ORGS more profitable? Estrella Immunopharma has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Orgenesis' return on equity of 0.00% beat Estrella Immunopharma's return on equity.Company Net Margins Return on Equity Return on Assets Estrella ImmunopharmaN/A -195.77% -157.28% Orgenesis -3,827.81%N/A -130.18% Do insiders & institutionals believe in ESLA or ORGS? 0.3% of Estrella Immunopharma shares are owned by institutional investors. Comparatively, 22.6% of Orgenesis shares are owned by institutional investors. 55.1% of Estrella Immunopharma shares are owned by company insiders. Comparatively, 5.7% of Orgenesis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has stronger earnings and valuation, ESLA or ORGS? Estrella Immunopharma has higher earnings, but lower revenue than Orgenesis. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEstrella ImmunopharmaN/AN/A-$7.31M-$0.26-3.88Orgenesis$662K14.57-$55.36MN/AN/A SummaryEstrella Immunopharma beats Orgenesis on 7 of the 13 factors compared between the two stocks. Get Orgenesis News Delivered to You Automatically Sign up to receive the latest news and ratings for ORGS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORGS vs. The Competition Export to ExcelMetricOrgenesisPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.65M$6.48B$5.35B$8.38BDividend YieldN/A2.66%5.22%4.10%P/E RatioN/A8.9226.8419.71Price / Sales14.57250.96391.39116.98Price / CashN/A65.8538.2534.62Price / Book-0.316.466.794.50Net Income-$55.36M$143.98M$3.23B$248.18M7 Day Performance6.35%3.04%4.07%1.14%1 Month Performance-18.95%7.44%12.52%15.18%1 Year PerformanceN/A-2.46%16.83%6.55% Orgenesis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORGSOrgenesisN/A$2.01flatN/AN/A$9.65M$662,000.000.00150Gap DownESLAEstrella Immunopharma1.5258 of 5 stars$1.03flat$16.00+1,453.4%-6.7%$37.25MN/A-3.96N/APositive NewsGap DownALZNAlzamend Neuro3.0334 of 5 stars$5.15-13.0%$20.00+288.3%-93.9%$37.13MN/A0.004Gap DownHigh Trading VolumeOSTXOS Therapies2.0568 of 5 stars$1.70-12.8%$18.00+958.8%N/A$36.83MN/A0.00N/AGap DownRVPHReviva Pharmaceuticals3.4462 of 5 stars$0.78-4.8%$10.00+1,182.1%-32.5%$36.46MN/A-0.705News CoverageEarnings ReportAnalyst ForecastCELUCelularity0.1961 of 5 stars$1.52-9.0%N/A-25.8%$36.19M$48.20M-0.57220News CoverageITRMIterum Therapeutics2.273 of 5 stars$1.01-1.0%$9.00+791.1%-34.3%$36.04MN/A-0.7710TNYATenaya Therapeutics3.4626 of 5 stars$0.41-0.7%$6.25+1,420.3%-88.8%$36.01MN/A-0.29110Gap DownNRXPNRx Pharmaceuticals1.9528 of 5 stars$2.08+2.0%$28.50+1,270.2%-31.5%$35.83MN/A-0.972News CoverageEarnings ReportGap UpELYMEliem TherapeuticsN/A$1.19flatN/A-84.5%$35.41MN/A-2.259RANIRani Therapeutics2.0823 of 5 stars$0.61-16.0%$12.00+1,857.6%-85.7%$35.24M$1.03M-0.58110Analyst RevisionGap Down Related Companies and Tools Related Companies Estrella Immunopharma Alternatives Alzamend Neuro Alternatives OS Therapies Alternatives Reviva Pharmaceuticals Alternatives Celularity Alternatives Iterum Therapeutics Alternatives Tenaya Therapeutics Alternatives NRx Pharmaceuticals Alternatives Eliem Therapeutics Alternatives Rani Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ORGS) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Orgenesis Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Orgenesis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ORGS Stock Free ORGS Stock Alerts